| It is an intravenously administered drug which requires metabolic activation by microsomal liver enzymes to produce biologically active metabolites Urinary metabolites of ifosfamide are cytotoxic and alkylated metabolites of ifosfamide have been shown to interact with DNA which result in the formation of DNA-DNA cross links. Ifosfamide is extensively metabolised in humans and the metabolic pathway appear to be saturated at high doses
| Composition : | 1000mg, 2000mg | | Indications : | Used as third line chemotherapy of germ cell testicular cancer. Should ordinarily be used in combination with a prophylactic agent for haemorrhagic cystitis, such as mesna. | | Contraindications : | Heamorrhagic cystitis might be frequently observed so pre-treatment urine analysis to rule out microscopic haematuria is recommended severe myelosuppression might occur when given in combination with other chemotherapeutic agents. | | Safety Profile : | Pregnancy: Animal studies show teratogenic and embryotoxic effects.
Paediatrics use: Safety and effectiveness in children have not been established. | | Adverse Effects : | Alopecia, nausea and vomiting are the most common side effects. The dose limiting toxicities are myelosuppression and urotoxicity. CNS side effects include somnolence, confusion, depressive psychosis and hallucinations. | | Dosage : | Over 30 mins. or more administered intravenously at a dose of 1.2 gm/m² day for five consecutive days. Treatment is repeated every 3 weeks or after recovery 3 weeks or after recovery from haematologic toxicity (Platelets> 100,000/ul, WBC> 4000/ul) To prevent bladder toxicity: it is given with extensive hydration (At least 2L/day, orally or intra-venous) along with the usage of a protector such as mesna | | Purity : | Not less than 99%. | |
 |
© Health Biotech Limited. All Rights Reserved (Terms of Use)
